EXACT Sciences — Q1 2025 Earnings Presentation
19 slides from EXACT Sciences's earnings presentation, May 1, 2025
Slide 1: First-quarter 2025 earnings call
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. First-quarter 2025 earnings call May 1, 2025 EXACT SCIENCES 1
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub
Slide 3: Exact Sciences is a global leader in advanced cancer diagnostics
Exact Sciences is a global leader in advanced cancer diagnostics with a differentiated platform OUR FOOTPRINT OUR IMPACT & SCALE OUR CAPABILITIES 7,000+ 1.2M Proprietary scientific platform detects cancer earlier and accurately global team members test results in 1Q25 ~200K $707M Powerful commercial
Slide 4: Core revenue grew 11% in 1Q25
Core revenue grew 11% in 1Q25 Core revenue Screening revenue Precision Oncology core revenue $707M $635M +11% $540M $475M +14% $161M $167M +4% 1Q24 1Q25 1Q24 1Q25 1Q24 1Q25 Please refer to our first-quarter 2025 earnings release at exactsciences.com for discussion of non-GAAP financial measures and
Slide 5: Profitability continued to improve in 1Q25
Profitability continued to improve in 1Q25, enabling investment to support the launch of new products Adjusted EBITDA Free cash flow Adjusted EBITDA margin $63M 9% $0M +$24M +280 bps $39M +$120M 6% -$120M 1Q24 1Q25 1Q24 1Q25 Please refer to our first-quarter 2025 earnings release at exactsciences.co
Slide 6: Updated 2025 guidance
Updated 2025 guidance $ ∆ at Prior guidance May 1 update midpoint Total revenue $3.025 – 3.085B $3.070 – 3.120B +$40M Screening $2.350 - 2.390B $2.390 – 2.425B +$38M Precision Oncology $675 - 695M $680 - 695M +$3M Adj. EBITDA $410 - 440M $425 - 455M +$15M Exact Sciences guidance provided May 1, 2025
Slide 7: Leading indicators of commercial productivity improvement are positive
Leading indicators of commercial productivity improvement are positive Reach Breadth ~30% >190K Y/Y increase in ordering providers in 1Q25, customer engagement up nearly 10% Y/Y Source: Exact Sciences internal data EXACT SCIENCES 7
Slide 8: Our Cologuard Plus test can revolutionize non-invasive tests in screening
Our Cologuard PlusTM test can revolutionize non-invasive tests in screening for colorectal cancer Progress with multi-cancer early detection and upcoming milestones Improved performance Cologuard® first. Covered for Medicare patients Colonoscopy as needed. Make available as a lab Included in quality
Slide 9: The Oncodetect test uses unique science to predict and detect cancer relapses earlier
The OncodetectTM test uses unique science to predict and detect cancer relapses earlier A positive Oncodetect Oncodetect patient is detects relapse ~50X >2 years more likely to recur sooner than standard of care Source: R. Schoen et al., Journal of Surgical Oncology (2025) EXACT SCIENCES 9
Slide 10: Advancing a blood-based colon cancer screening test for patients
Advancing a blood-based colon cancer screening test for patients FOCUS ProgressAREAS AHEAD early with multi-cancer OF PIVOTAL detection and READOUT upcoming milestones IT readiness Lab readiness Sample readiness Make available as a lab BLUE-C study results developed mid-summer test in in 2025 2025 E
Slide 11: Cancerguard screens for multiple types of cancer through a single blood draw
CancerguardTM screens for multiple types of cancer through a single blood draw Problem Solution Progress with Cancerguard Progress with multi-cancer early and upcoming detection milestones and upcoming milestones Published data showing 67% 14% sensitivity for 6 deadliest cancers Generate real-world
Slide 12: Our purpose is to help eradicate cancer by preventing it, detecting it earlier
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment EXACT SCIENCES 12
Slide 13: Exact Sciences
EXACT SCIENCES 13
Slide 14: Selected Unaudited Financial Information
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Three Months Ended March 31, 2025 2024 Revenue $ 706,785 $ 637,524 Cost of sales 206,238 191,201 Gross profit 500,547 446,323 Operating ex
Slide 15: Condensed Consolidated Balance Sheets
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) March 31, December 31, 2025 2024 Assets Cash and cash equivalents $ 347,127 $ 600,889 Marketable securities 439,048 437,137 Accounts receivable, net 279,800 248,968 Invent
Slide 16: Reconciliation of Core Revenue
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP Three Months Ended March 31, 2025 2024 % Change Screening $ 540,007 $ 474,798 14 % Precision Oncology 166,778 162,726 2 % Total $ 706,785 $ 637,524 11 % Non-GAAP Three Month
Slide 17: EBITDA and Adjusted EBITDA Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended March 31, 2025 2024 Net loss $ (101,215) $ (110,228) Interest expense 9,978 7,943 Income tax expense 224 1,806 Investment income (4,997) (6,213) De
Slide 18: Reconciliation of U.S. GAAP to Non-GAAP Measures
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of U.S. GAAP to Non-GAAP Measures (Amounts in thousands) Three Months Ended March 31, 2025 Research & General & Development Sales & Marketing Administrative Loss from Income Tax Benefit Gross Profit Expenses(6) Expens
Slide 19: Statements of Cash Flows and Reconciliation of Free Cash Flow
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) Three Months Ended March 31, 2025 2024 Net cash provided by (used in) operating activities 30,809 (82,311) Net cash used in